47 ud af 47 tidsskrifter valgt, søgeord (HIV, human immunodeficiency virus, AIDS) valgt, emner højest 30 dage gamle, sorteret efter nyeste først.
122 emner vises.
101
Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial
Clinical Infectious Diseases, 10.04.2024
Tilføjet 10.04.2024
Abstract Background Children living with HIV(CLWH) are at high risk of tuberculosis(TB) and face poor outcomes, despite antiretroviral treatment(ART). We evaluated outcomes in CLWH and HIV-uninfected children treated for non-severe TB in the SHINE trial.Methods SHINE was a randomized trial that enrolled children aged
Læs mere
Tjek på PubMed
102
Associations between intravaginal practices and incidence of sexually transmitted infections and bacterial vaginosis among women enrolled in the dapivirine vaginal ring trial (The Ring Study) in southwestern Uganda: a retrospective secondary analysis
Kusemererwa, S., Ruzagira, E., Onyango, M., Kabarambi, A., Abaasa, A.
BMJ Open, 9.04.2024
Tilføjet 9.04.2024
ObjectivesWe assessed associations between intravaginal practices (IVPs) and the incidence of sexually transmitted infections (STIs) and bacterial vaginosis (BV) among women using the dapivirine vaginal ring (DVR) or placebo vaginal ring in southwestern Uganda. MethodsThis was a retrospective secondary analysis of data collected from women at risk of HIV infection recruited into the Ring Study. The latter evaluated the safety and efficacy of the DVR between 2013 and 2016. At baseline, a behavioural questionnaire was administered to obtain information on sexual activity and IVP (exposure) defined as; insertion inside the vagina of any items aimed at cleaning the vagina for any reason before, during or after sex other than practices to manage menses. Each participant self-inserted the DVR/placebo and replaced it every 4 weeks for 2 years. Outcomes were diagnosis of STIs, that is, Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis (TV), HIV and BV. The incidence rate of STI/BV was estimated, overall, by IVP and trial arm in single-event-per-participant and multiple-event-per-participant analyses. ResultsOf the 197 women enrolled, 66 (33.5%) were
Læs mere
Tjek på PubMed
103
Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China
BMC Infectious Diseases, 9.04.2024
Tilføjet 9.04.2024
Abstract Background Highly active antiretroviral therapy (HAART) has been able to improve the immune system function and survival of human immunodeficiency virus (HIV) patients. However, Patients coinfected with HIV and hepatitis B virus (HBV) are more likely to develop end-stage liver disease (ESLD) than those infected with HBV alone. Consequently, liver transplantation is often required for these patients. This study evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-HBV coinfected patients in China. Methods We conducted a retrospective analysis on all HIV-HBV coinfected patients that underwent OLT from April 1, 2019 to December 31, 2021 and their outcomes were compared to all HBV monoinfected patients undergoing OLT during the same period. Patient outcomes were determined, including cumulative survival, viral load, CD4 T-cell count and postoperative complications. Results The median follow-up of HIV recipients was 36 months after OLT (interquartile range 12–39 months). Almost all patients had stable CD4 T-cell count (> 200 copies/ul), undetectable HBV DNA levels, and undetectable HIV RNA load during follow-up. The 1-, 2-, and 3-year posttransplant survival rates were 85.7% for the HIV group (unchanged from 1 to 3 years) versus 82.2%, 81.2%, and 78.8% for the non-HIV group. Cumulative survival among HIV-HBV coinfected recipients was not significantly different from the HBV monoinfected recipients (log-rank test P = 0.692). The percentage of deaths attributed to infection was comparable between the HIV and non-HIV groups (14.3% vs. 9.32%, P = 0.665). Post OLT, there was no significant difference in acute rejection, cytomegalovirus infection, bacteremia, pulmonary infection, acute kidney injury, de novo tumor and vascular and biliary complications. Conclusions Liver transplantation in patients with HIV-HBV coinfection yields excellent outcomes in terms of intermediate- or long-term survival rate and low incidence of postoperative complications in China. These findings suggest that OLT is safe and feasible for HIV-HBV coinfected patients with ESLD. Trial registration Chinese Clinical Trial Registry (ChiCTR2300067631), registered 11 January 2023.
Læs mere
Tjek på PubMed
104
A systematic review on antibiotic therapy of cutaneous bacillary angiomatosis not related to major immunocompromising conditions: from pathogenesis to treatment
BMC Infectious Diseases, 9.04.2024
Tilføjet 9.04.2024
Abstract Background Cutaneous bacillary angiomatosis (cBA) is a vascular proliferative disorder due to Bartonella spp. that mostly affects people living with HIV (PLWH), transplanted patients and those taking immunosuppressive drugs. Since cBA is mostly related to these major immunocompromising conditions (i.e., T-cell count impairment), it is considered rare in relatively immunocompetent patients and could be underdiagnosed in them. Moreover, antimicrobial treatment in this population has not been previously investigated. Methods We searched the databases PubMed, Google Scholar, Scopus, OpenAIRE and ScienceDirect by screening articles whose title included the keywords “bacillary” AND “angiomatosis” and included case reports about patients not suffering from major immunocompromising conditions to provide insights about antibiotic treatments and their duration. Results Twenty-two cases of cBA not related to major immunocompromising conditions were retrieved. Antibiotic treatment duration was shorter in patients with single cBA lesion than in patients with multiple lesions, including in most cases macrolides and tetracyclines. Conclusions cBA is an emerging manifestation of Bartonella spp. infection in people not suffering from major immunocompromising conditions. Until evidence-based guidelines are available, molecular tests together with severity and extension of the disease can be useful to personalize the type of treatment and its duration.
Læs mere
Tjek på PubMed
105
Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1
Hardik ChandasanaRajendra SinghKimberly AdkisonMounir Ait-KhaledTeodora Pene Dumitrescu1Clinical Pharmacology Modeling & Simulation, GSK, Collegeville, Pennsylvania, USA2ViiV Healthcare, Durham, North Carolina, USA3ViiV Healthcare Ltd., Brentford, United Kingdom, Sean Wasserman
Antimicrobial Agents And Chemotherapy, 9.04.2024
Tilføjet 9.04.2024
106
Contributions of cerebral white matter hyperintensities, age, and pedal perception to postural sway in people living with HIV
Sullivan, Edith V.; Zahr, Natalie M.; Zhao, Qingyu; Pohl, Kilian M.; Sassoon, Stephanie A.; Pfefferbaum, Adolf
AIDS, 7.04.2024
Tilføjet 7.04.2024
Objective: With aging, people living with HIV (PLWH) have diminishing postural stability that increases liability for falls. Factors and neuromechanisms contributing to instability are incompletely known. Brain white matter abnormalities seen as hyperintense (WMH) signals have been considered to underlie instability in normal aging and PLWH. We questioned whether sway-WMH relations endured after accounting for potentially relevant demographic, physiological, and HIV-related variables. Design: Mixed cross-sectional/longitudinal data acquired over 15 years in 141 PLWH and 102 age-range matched controls, 25–80 years old. Methods: Multimodal structural MRI data were quantified for 7 total and regional WMH volumes. Static posturography acquired with a force platform measured sway path length separately with eyes closed and eyes open. Statistical analyses used multiple regression with mixed modeling to test contributions from non-MRI and non-path data on sway path-WMH relations. Results: In simple correlations, longer sway paths were associated with larger WMH volumes in PWLH and controls. When demographic, physiological, and HIV-related variables were entered into multiple regressions, the sway-WMH relations under both vision conditions in the controls were attenuated when accounting for age and 2-point pedal discrimination. Although the sway-WMH relations in PLWH were influenced by age, 2-point pedal discrimination, and years with HIV infection, the sway-WMH relations endured for 5 of the 7 regions in the eyes-open condition. Conclusions: The constellation of age-related increasing instability while standing, degradation of brain white matter integrity, and peripheral pedal neuropathy is indicative of advancing fraility and liability for falls as people age with HIV infection. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere
Tjek på PubMed
107
Forecasting the effect of HIV-targeted interventions on the age distribution of people living with HIV: a case study from Kenya
Schnure, Melissa C.; Kasaie, Parastu; Dowdy, David W.; Genberg, Becky L.; Kendall, Emily A.; Fojo, Anthony T.
AIDS, 7.04.2024
Tilføjet 7.04.2024
Objectives: Expansion of ART and increases to life expectancy have led to aging among people living with HIV (PWH). Design: Kenyan decisionmakers need accurate forecasts of the age distribution of PWH to inform future policies. Methods: We developed a model of HIV in Kenya, calibrated to historical estimates of HIV epidemiology. We forecasted changes in population size and age distribution of new HIV infections and PWH under the status quo and under scale-up of HIV services. Results: Without scale-up, new HIV infections were forecasted to fall from 34,000 [28,000–41,000] in 2025 to 29,000 [15,000–57,000] in 2040; the percent of new infections occurring among persons over 30 increased from 33% [20–50%] to 40% [24–62%]. The median age of PWH increased from 39 years [38–40] in 2025 to 43 years [39–46] in 2040, and the percent of PWH over age 50 increased from 26% [23–29%] to 34% [26–43%]. Under the full intervention scenario, new infections were forecasted to fall to 6,000 [3,000–12,000] in 2040. The percent of new infections occurring in people over age 30 increased to 52% [34–71%] in 2040, and there was an additional shift in the age structure of PWH (forecasted median age of 46 [43–48] and 40% [33–47%] over age 50). Conclusions: PWH in Kenya are forecasted to age over the next 15 years; improvements to the HIV care continuum are expected to contribute to the growing proportion of older PWH. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere
Tjek på PubMed
108
Global stability for age-infection-structured human immunodeficiency virus model with heterogeneous transmission
Infectious Disease Modelling, 8.02.2024
Tilføjet 8.02.2024
Publication date: Available online 7 February 2024 Source: Infectious Disease Modelling Author(s): Juping Zhang, Linlin Wang, Zhen Jin
Læs mere
Tjek på PubMed
109
Increasing age and duration of sex work among female sex workers in South Africa and implications for HIV incidence estimation: Bayesian evidence synthesis and simulation exercise
Infectious Disease Modelling, 23.01.2024
Tilføjet 23.01.2024
Publication date: Available online 23 January 2024 Source: Infectious Disease Modelling Author(s): Nanina Anderegg, Mariette Slabbert, Kholi Buthelezi, Leigh F. Johnson
Læs mere
Tjek på PubMed
110
Dynamics of a two-group model for assessing the impacts of pre-exposure prophylaxis, testing and risk behaviour change on the spread and control of HIV/AIDS in an MSM population
Infectious Disease Modelling, 21.11.2023
Tilføjet 21.11.2023
Publication date: Available online 20 November 2023 Source: Infectious Disease Modelling Author(s): Queen Tollett, Salman Safdar, Abba B. Gumel
Læs mere
Tjek på PubMed
111
Analysis of the impacts of treatments in a HIV/AIDS and Tuberculosis co-infected population under random perturbations
Infectious Disease Modelling, 16.11.2023
Tilføjet 16.11.2023
Publication date: Available online 15 November 2023 Source: Infectious Disease Modelling Author(s): Olusegun Michael Otunuga
Læs mere
Tjek på PubMed
112
Optimal therapy for HIV infection containment and virions inhibition
Infectious Disease Modelling, 15.11.2023
Tilføjet 15.11.2023
Publication date: Available online 14 November 2023 Source: Infectious Disease Modelling Author(s): Paolo Di Giamberardino, Daniela Iacoviello, Muhammad Zubair
Læs mere
Tjek på PubMed
113
Impact of differentiated service delivery models on retention in HIV care and viral suppression among people living with HIV in sub‐Saharan Africa: A systematic review and meta‐analysis of randomised controlled trials
George M. Bwire; Belinda J. Njiro; Harieth P. Ndumwa; Castory G. Munishi; Bonaventura C. Mpondo; Mathew Mganga; Emmanuel Mang'ombe; Muhammad Bakari; Raphael Z. Sangeda; Christopher R. Sudfeld; Japthet Killewo;
Reviews in Medical Virology, 11.11.2023
Tilføjet 11.11.2023
Differentiated service delivery (DSD) models, such as adherence clubs (ACs), are client‐centred approaches where clinically stable people living with HIV (PLHIV) meet to receive various services, including psychosocial support, brief symptoms screening, and refills of antiretroviral medications, among others. We conducted a review to assess the impact of DSD models, including ACs, on sustaining retention in care (RC) and achieving viral suppression (VS) among PLHIV in sub‐Saharan Africa. The review protocol was registered in PROSPERO (CRD42023418988). We searched the literature from PubMed, Scopus, Web of Science, Embase and Google Scholar from their inception through May 2023. Eligible randomised controlled trials of adherence clubs were reviewed to assess impact on retention and viral suppression. Random effect models were used to estimate the risk ratios (RR) and 95% confidence intervals (CI). The literature search yielded a total of 1596 records of which 16 randomised clinical trials were determined to be eligible. The trials were conducted in diverse populations among adults and children with a total of 13,886 participants. The RR between any DSD models and standard of care (SoC) was 1.09 (95% CI: 1.08–1.11, : 0%, :
Læs mere
Tjek på PubMed
114
Modulation of various host cellular machinery during COVID‐19 infection
Shivani Malvankar; Anjali Singh; Y. S. Ravi Kumar; Swetangini Sahu; Megha Shah; Yamini Murghai; Mahendra Seervi; Rupesh K. Srivastava; Bhupendra Verma;
Reviews in Medical Virology, 11.11.2023
Tilføjet 11.11.2023
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) emerged in December 2019, causing a range of respiratory infections from mild to severe. This resulted in the ongoing global COVID‐19 pandemic, which has had a significant impact on public health. The World Health Organization declared COVID‐19 as a global pandemic in March 2020. Viruses are intracellular pathogens that rely on the host\'s machinery to establish a successful infection. They exploit the gene expression machinery of host cells to facilitate their own replication. Gaining a better understanding of gene expression modulation in SARS‐CoV2 is crucial for designing and developing effective antiviral strategies. Efforts are currently underway to understand the molecular‐level interaction between the host and the pathogen. In this review, we describe how SARS‐CoV2 infection modulates gene expression by interfering with cellular processes, including transcription, post‐transcription, translation, post‐translation, epigenetic modifications as well as processing and degradation pathways. Additionally, we emphasise the therapeutic implications of these findings in the development of new therapies to treat SARS‐CoV2 infection.
Læs mere
Tjek på PubMed
115
Human immunodeficiency virus transmission—Mechanisms underlying the cell‐to‐cell spread of human immunodeficiency virus
Marta Calado; David Pires; Carolina Conceição; Quirina Santos‐Costa; Elsa Anes; José Miguel Azevedo‐Pereira;
Reviews in Medical Virology, 11.11.2023
Tilføjet 11.11.2023
Despite the success of combined antiretroviral therapy in controlling viral load and reducing the risk of human immunodeficiency virus (HIV) transmission, an estimated 1.5 million new infections occurred worldwide in 2021. These new infections are mainly the result of sexual intercourse and thus involve cells present on the genital mucosa, such as dendritic cells (DCs), macrophages (Mø) and CD4+ T lymphocytes. Understanding the mechanisms by which HIV interacts with these cells and how HIV exploits these interactions to establish infection in a new human host is critical to the development of strategies to prevent and control HIV transmission. In this review, we explore how HIV has evolved to manipulate some of the physiological roles of these cells, thereby gaining access to strategic cellular niches that are critical for the spread and pathogenesis of HIV infection. The interaction of HIV with DCs, Mø and CD4+ T lymphocytes, and the role of the intercellular transfer of viral particles through the establishment of the infectious or virological synapses, but also through membrane protrusions such as filopodia and tunnelling nanotubes (TNTs), and cell fusion or cell engulfment processes are presented and discussed.
Læs mere
Tjek på PubMed
116
Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence
Immunity, 4.11.2023
Tilføjet 4.11.2023
Publication date: Available online 2 November 2023 Source: Immunity Author(s): Yulong Wei, Timothy C. Davenport, Jack A. Collora, Haocong Katherine Ma, Delia Pinto-Santini, Javier Lama, Ricardo Alfaro, Ann Duerr, Ya-Chi Ho
Læs mere
Tjek på PubMed
117
Virus infection participates in the occurrence and development of human diseases through monoamine oxidase
Yujie Sun; Wen Liu; Bing Luo;
Reviews in Medical Virology, 8.09.2023
Tilføjet 8.09.2023
Monoamine oxidase (MAO) is a membrane‐bound mitochondrial enzyme that maintains the steady state of neurotransmitters and other biogenic amines in biological systems through catalytic oxidation and deamination. MAO dysfunction is closely related to human neurological and psychiatric diseases and cancers. However, little is known about the relationship between MAO and viral infections in humans. This review summarises current research on how viral infections participate in the occurrence and development of human diseases through MAO. The viruses discussed in this review include hepatitis C virus, dengue virus, severe acute respiratory syndrome coronavirus 2, human immunodeficiency virus, Japanese encephalitis virus, Epstein‐Barr virus, and human papillomavirus. This review also describes the effects of MAO inhibitors such as phenelzine, clorgyline, selegiline, M‐30, and isatin on viral infectious diseases. This information will not only help us to better understand the role of MAO in the pathogenesis of viruses but will also provide new insights into the treatment and diagnosis of these viral diseases.
Læs mere
Tjek på PubMed
118
A systematic review on the molecular and clinical association between Human Papillomavirus and Human Immunodeficiency Virus co‐infection in Head, Neck and Oral squamous cell carcinoma
Shreya Chakraborty; Kanagavalli Ramasubbu; Manosi Banerjee; Menaka Priya Balaji; Yamini Vinayagam; Devi Rajeswari V;
Reviews in Medical Virology, 8.09.2023
Tilføjet 8.09.2023
Head and neck cancer, one of the most commonly prevalent malignancies globally is a complex category of tumours that comprises cancers of the oral cavity, pharynx, and larynx. A specific subgroup of such cancers has been found with some unique chromosomal, therapeutic, and epidemiologic traits with the possibility of affecting via co‐infection. About 25% of all head and neck cancers in the population are human papillomavirus infection (HPV)‐associated, typically developing in the oropharynx, which comprises the tonsils. In the period of efficient combined antiviral treatment, HPV‐positive oral cancers are also becoming a significant contributor to illness and fatality for Human Immunodeficiency Virus (HIV)‐infected persons. Although the prevalence and historical background of oral HPV transmission are not thoroughly understood, it seems likely that oral HPV transmission is relatively frequent in HIV‐infected people when compared to the overall population. Therefore, there is a need to understand the mechanisms leading to this co‐infection, as there is very little research related to that. Hence, this study mainly focus on the therapeutical and biomedical analysis of HPV and HIV co‐infection in the above‐mentioned cancer, including oral squamous cell carcinoma.
Læs mere
Tjek på PubMed
119
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates
Immunity, 2.08.2023
Tilføjet 2.08.2023
Publication date: Available online 1 August 2023 Source: Immunity Author(s): Wenhui He, Tianling Ou, Nickolas Skamangas, Charles C. Bailey, Naomi Bronkema, Yan Guo, Yiming Yin, Valerie Kobzarenko, Xia Zhang, Andi Pan, Xin Liu, Jinge Xu, Lizhou Zhang, Ava E. Allwardt, Debasis Mitra, Brian Quinlan, Rogier W. Sanders, Hyeryun Choe, Michael Farzan
Læs mere
Tjek på PubMed
120
Humoral immune response to two doses of COVID‐19 mRNA‐based vaccines in people living with HIV: A systematic review and meta‐analysis
Negin Farhadian; Sara Sharifi; Mahdi Taghadosi; Maryam Farhadian; Siavash Vaziri;
Reviews in Medical Virology, 10.07.2023
Tilføjet 10.07.2023
People living with HIV (PLWH) are susceptible to severe COVID‐19 infection and hence this fragile population has prioritised vaccination. This systematic review and meta‐analysis aimed to assess the humoral immune response after receiving two doses schedule of COVID‐19 mRNA vaccinations in this high‐risk population. A systematic electronic search on the PubMed database and manual searches were performed for relevant articles until 30 Sep 2022. Two outcomes of interest were seroconversion rates and anti‐spike receptor binding domain (anti‐S‐RBD) antibody titres at the median time of 14–35 days following two‐dose vaccination among PLWH. Nineteen cohorts and one cross‐sectional study were eligible for inclusion in this study. The pooled estimate of seroconversion rate after receiving two doses of mRNA vaccination schedule were 98.4% and 75.2% among PLWH with CD4>500 cells/mm and CD4500 cells/mm had a 51% likelihood of having positive anti‐Spike‐RBD immunoglobulin G (IgG) (OR: 0.509, 95% CI: 0.228, 1.133, = 0.098) post‐vaccination and this value was only 1.4% (OR: 0.014, 95% CI: 0.002, 0.078, = 0.000) for PLWH with CD4500 cells/mm and healthy controls ( = 0.06). The pooled median of anti‐S‐RBD IgG values were 1461.93 binding antibody units (BAU)/ml and 457.41 BAU/ml in PLWH with CD4>500 cells/mm and CD4
Læs mere
Tjek på PubMed
121
Efficacy and safety of long‐acting cabotegravir versus oral tenofovir disoproxil fumarate‐emtricitabine as HIV pre‐exposure prophylaxis: A systematic review and meta‐analysis
Xiu Chen; Jun Li; Liqiu Kou; Xiaolu Xie; Deqing Wei; Yaling Li;
Reviews in Medical Virology, 10.07.2023
Tilføjet 10.07.2023
WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre‐exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection. However, due to social, psychological and other reasons, the compliance with daily oral TDF‐FTC in real life is low. Long‐acting cabotegravir is currently the only long‐acting drug approved by the U.S. Food and Drug Administration (FDA) for HIV PrEP. Due to the long dosing interval (8 weeks), long‐acting cabotegravir has low compliance requirements for people at high risk of HIV infection. We aimed to discuss the feasibility of long‐acting cabotegravir to replace TDF‐FTC as HIV PrEP based on efficacy and safety analyses. Randomized controlled trials were retrieved, and R software was used for meta‐analysis after data extraction. and discussion: Results of the meta‐analysis showed that compared with TDF‐FTC, long‐acting cabotegravir was associated with a lower risk of HIV infection (HR = 0.22, 95% CI: 0.08–0.59,
Læs mere
Tjek på PubMed
122
Site-specific development and progressive maturation of human tissue-resident memory T cells over infancy and childhood
Immunity, 8.07.2023
Tilføjet 8.07.2023
Publication date: Available online 7 July 2023 Source: Immunity Author(s): Thomas J. Connors, Rei Matsumoto, Shivali Verma, Peter A. Szabo, Rebecca Guyer, Joshua Gray, Zicheng Wang, Puspa Thapa, Pranay Dogra, Maya M.L. Poon, Ksenia Rybkina, Marissa C. Bradley, Emma Idzikowski, James McNichols, Masaru Kubota, Kalpana Pethe, Yufeng Shen, Mark A. Atkinson, Maigan Brusko, Todd M. Brusko
Læs mere
Tjek på PubMed